Initial FLAG-Ida Outperforms 7+3 for High-Risk AML Initial FLAG-Ida Outperforms 7+3 for High-Risk AML

A treatment commonly used as a salvage regimen for relapsed/refractory acute myelogenous leukemia (AML) showed better results than did standard treatment when used as initial induction therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news